Product Description
Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully qualified, fraud-free Belviq-related cancer cases. Here at Leading Justice, we can custom tailor your firm’s Belviq advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Belviq cancer advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is evaluated to determine whether it qualifies for another type of claim. By using innovative approaches to target contacts specifically related to Belviq and side effects like lung cancer, pancreatic cancer and colorectal cancer, Leading Justice will increase your firm’s Belviq caseload. If you are interested in helping victims of Belviq cancer side effects, our direct advertising strategies and extensive consumer reach at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being spent in the best way possible.
Each law firm we work with at Leading Justice plays a critical role in determining how we categorize claims as qualified or not. And while our experience working with plaintiff law firms allows us to recognize a great case when we see one, we will customize our Belviq cancer intake specifications to the exact criteria you are seeking. So, if your firm has specific Belviq qualifying case criteria you want us to use, we can train our intake specialists to apply the criteria to each phone call and email they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of Belviq cancer data with no chance of fraud.
Belviq Cancer Litigation
Before being removed from the U.S. market in February 2020, Belviq (lorcaserin) was a popular weight loss medication prescribed to obese individuals and overweight individuals with at least one other weight-related condition, such as hypertension or type 2 diabetes. The diet drug was approved by the U.S. Food and Drug Administration (FDA) in 2012 and was believed to work by selectively activating receptors in the brain that trigger feelings of satiety and satisfaction, in order to help obese individuals consume less and lose weight. Belviq was the first new prescription diet drug in 13 years to be approved as a weight loss aid for the 40% of Americans who are considered obese. Unfortunately, we now know that people who took Belviq for six months or more may be at risk for lung cancer, colorectal cancer, pancreatic cancer or other types of cancer.
Upon approving Belviq in 2012, the FDA required the manufacturer of the weight loss drug to conduct a safety clinical trial to evaluate cardiovascular outcomes in users and determine whether the medication was linked to heart problems. The clinical trial lasted from 2014 to 2018, and when the FDA conducted a preliminary analysis of the data, it found that patients taking Belviq instead faced an increased risk of cancer. The FDA warned Belviq users about the potential risk of cancer associated with the diet drug in January 2020, and by February 2020, the agency had requested the withdrawal of Belviq and Belviq XR from the market due to the elevated cancer risk. The FDA warned in its withdrawal request that more patients taking lorcaserin (Belviq) were diagnosed with cancer compared to those taking a placebo and stated that “the risks of lorcaserin outweigh its benefits based on our completed review of results from a randomized clinical trial assessing safety.” As more information is reported about the potential risk of lung, pancreatic and colorectal cancer from Belviq, Belviq maker Eisai Inc. is expected to face hundreds, if not thousands, of cancer lawsuits.
